A Phase 1 Study of JNJ-89402638 for Unresectable Metastatic Colorectal Cancer and Other Gastrointestinal Malignancies
Latest Information Update: 12 Mar 2026
At a glance
- Drugs JNJ 89402638 (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- Sponsors Janssen Research & Development
Most Recent Events
- 17 Feb 2026 Planned number of patients changed from 170 to 220.
- 10 Nov 2025 Planned End Date changed from 28 Jul 2028 to 19 Jul 2028.
- 22 Jul 2025 Planned End Date changed from 19 Jul 2028 to 28 Jul 2028.